Risk Disclosure: This website's content is not investment advice and offers no trading guidance or related services. Per regulations from the PBOC and other authorities, users must be aware of virtual currency risks. Contact us / [email protected] ICP License: 琼ICP备2022009338号
TechFlow, July 28 — According to Business Insider, NASDAQ-listed biopharmaceutical company Liminatus Pharma (NASDAQ: LIMN) announced today its plan to establish a subsidiary named "American BNB Strategy," aiming to raise and phase-invest up to $500 million into Binance's native token BNB. The company stated this move is based on the long-term growth potential and resilience of the BNB ecosystem, rather than short-term speculation.
According to BusinessInsider, Nasdaq-listed biopharmaceutical company Liminatus Pharma (NASDAQ: LIMN) announced today its plan to establish a subsidiary named "American BNB Strategy," aiming to raise and invest up to $500 million in Binance's native token BNB in phases. The company stated that this move is based on the long-term growth potential and resilience of the BNB ecosystem, rather than short-term speculation.
Navigating Web3 tides with focused insights
